From the original announcement of acceptance of submission:
Acrux has submitted an ANDA application to the FDA for Lidocaine 2.5% and Prilocaine
2.5% cream, which has now been accepted for review
• Annual sales for the product were US$35m as measured by IQVIA 1
• The product is used as a topical anaesthetic
• The announcement marks Acrux’s third product accepted for review by the FDA
So... kinda? Bit of both?
Add to My Watchlist
What is My Watchlist?
